Jean Cui

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Li Sun, Chris Liang, Sheri Shirazian et al. · Journal of Medicinal Chemistry · 2003 · 520 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

Nikolaus Schiering, Stefan Knapp, M. Marconi et al. · Proceedings of the National Academy of Sciences · 2003 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Sai‐Hong Ignatius Ou, Jean Cui, Alexa B. Schrock et al. · Lung Cancer · 2017 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

Sergei Timofeevski, Michele McTigue, Kevin Ryan et al. · Biochemistry · 2009 · 102 citations · Full text

Life Sciences, Biochemistry, Oncology +17

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis

Niki Karachaliou, Imane Chaib, Andrés F. Cardona et al. · EBioMedicine · 2018 · 79 citations · Full text

Medicine, Cancer Biology, Oncology +12